CN105658664A - 含有Fc的多肽的稳定化 - Google Patents

含有Fc的多肽的稳定化 Download PDF

Info

Publication number
CN105658664A
CN105658664A CN201480046222.5A CN201480046222A CN105658664A CN 105658664 A CN105658664 A CN 105658664A CN 201480046222 A CN201480046222 A CN 201480046222A CN 105658664 A CN105658664 A CN 105658664A
Authority
CN
China
Prior art keywords
polypeptide
antibody
cells
sequence
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480046222.5A
Other languages
English (en)
Chinese (zh)
Inventor
G.肯南
J.拉瓦李
F.W.雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CN202610132063.5A priority Critical patent/CN121930334A/zh
Publication of CN105658664A publication Critical patent/CN105658664A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
CN201480046222.5A 2013-07-31 2014-07-30 含有Fc的多肽的稳定化 Pending CN105658664A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610132063.5A CN121930334A (zh) 2013-07-31 2014-07-30 含有Fc的多肽的稳定化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31
US61/860800 2013-07-31
PCT/US2014/048908 WO2015017548A2 (en) 2013-07-31 2014-07-30 Stabilization of fc-containing polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610132063.5A Division CN121930334A (zh) 2013-07-31 2014-07-30 含有Fc的多肽的稳定化

Publications (1)

Publication Number Publication Date
CN105658664A true CN105658664A (zh) 2016-06-08

Family

ID=52432568

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480046222.5A Pending CN105658664A (zh) 2013-07-31 2014-07-30 含有Fc的多肽的稳定化
CN202610132063.5A Pending CN121930334A (zh) 2013-07-31 2014-07-30 含有Fc的多肽的稳定化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610132063.5A Pending CN121930334A (zh) 2013-07-31 2014-07-30 含有Fc的多肽的稳定化

Country Status (15)

Country Link
US (3) US20160193295A1 (cg-RX-API-DMAC7.html)
EP (1) EP3027647A4 (cg-RX-API-DMAC7.html)
JP (2) JP2016526909A (cg-RX-API-DMAC7.html)
KR (3) KR20250152665A (cg-RX-API-DMAC7.html)
CN (2) CN105658664A (cg-RX-API-DMAC7.html)
AU (3) AU2014296215A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016002219A2 (cg-RX-API-DMAC7.html)
CA (1) CA2919076C (cg-RX-API-DMAC7.html)
CL (1) CL2016000232A1 (cg-RX-API-DMAC7.html)
EA (1) EA035319B1 (cg-RX-API-DMAC7.html)
HK (1) HK1224203A1 (cg-RX-API-DMAC7.html)
IL (1) IL243690B (cg-RX-API-DMAC7.html)
MX (2) MX2016001165A (cg-RX-API-DMAC7.html)
SG (1) SG11201600734YA (cg-RX-API-DMAC7.html)
WO (1) WO2015017548A2 (cg-RX-API-DMAC7.html)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
CN110234355A (zh) * 2017-02-01 2019-09-13 时迈药业 单体人IgG1 Fc和双特异性抗体
WO2022032660A1 (zh) * 2020-08-14 2022-02-17 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CN114401998A (zh) * 2019-09-18 2022-04-26 诺华股份有限公司 Nkg2d融合蛋白及其用途
CN114426974A (zh) * 2020-10-29 2022-05-03 洛阳普泰生物技术有限公司 非洲猪瘟病毒CD2v蛋白及由其制备的试剂盒和抗体
WO2023025120A1 (en) * 2021-08-24 2023-03-02 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
CN116064562A (zh) * 2022-10-28 2023-05-05 江南大学 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途
CN116194487A (zh) * 2020-08-21 2023-05-30 亚洲大学校产学协力团 由重链恒定区和轻链恒定区组成的γ恒定区（Cγ1）和ε恒定区（Cε2-4）融合的抗体片段及其用途
CN116284455A (zh) * 2023-04-17 2023-06-23 北京康乐卫士生物技术股份有限公司 一种带状疱疹病毒疫苗的嵌合抗原及其应用
CN116970059A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CN117120479A (zh) * 2020-11-02 2023-11-24 阿特拉斯公司 Sap fc融合蛋白及其使用方法
CN118344462A (zh) * 2024-06-18 2024-07-16 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN119613573A (zh) * 2025-02-14 2025-03-14 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN119735654A (zh) * 2025-02-27 2025-04-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用
WO2025162458A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 融合抗体及其制备和应用
CN120623322A (zh) * 2025-08-14 2025-09-12 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用
CN120923615A (zh) * 2025-08-15 2025-11-11 成都蓉生药业有限责任公司 一种人IgG1 Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG1 Fc变体的制备方法和应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
CN106687128B (zh) * 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
EP3233920B1 (en) 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
CA3025162A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
WO2018005226A2 (en) * 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
US20200157172A1 (en) * 2017-07-07 2020-05-21 HANMl PHARM. CO., LTD. Novel therapeutic enzyme fusion protein and use thereof
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
EP3708661A4 (en) 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
BR112021002032A2 (pt) 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
CA3141130A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
US20220227888A1 (en) 2019-06-07 2022-07-21 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
KR102899743B1 (ko) * 2019-12-11 2025-12-12 주식회사 엘지화학 O-글리코실화 가능한 폴리펩타이드 영역 및 gdf15를 포함하는 융합 폴리펩타이드
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP7481856B2 (ja) 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
BR112023008317A2 (pt) * 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso
EP4240770A1 (en) 2020-11-06 2023-09-13 Amgen Research (Munich) GmbH Polypeptide constructs selectively binding to cldn6 and cd3
WO2022120286A1 (en) * 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
EP4762084A1 (de) * 2023-08-17 2026-06-24 Gottfried Wilhelm Leibniz Universität Hannover (LUH) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070098712A1 (en) * 1997-05-02 2007-05-03 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2011063348A1 (en) * 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
CN102643344A (zh) * 2003-07-26 2012-08-22 新兴产品开发西雅图有限公司 结合构建体及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (en) * 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101866623B1 (ko) * 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
PT3156420T (pt) 2010-12-06 2019-05-27 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070098712A1 (en) * 1997-05-02 2007-05-03 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CN102643344A (zh) * 2003-07-26 2012-08-22 新兴产品开发西雅图有限公司 结合构建体及其使用方法
WO2011063348A1 (en) * 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117024560A (zh) * 2016-12-22 2023-11-10 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CN116970059A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CN110234355A (zh) * 2017-02-01 2019-09-13 时迈药业 单体人IgG1 Fc和双特异性抗体
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
CN114401998A (zh) * 2019-09-18 2022-04-26 诺华股份有限公司 Nkg2d融合蛋白及其用途
CN116096736A (zh) * 2020-08-14 2023-05-09 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CN116096736B (zh) * 2020-08-14 2026-07-10 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
WO2022032660A1 (zh) * 2020-08-14 2022-02-17 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CN116194487A (zh) * 2020-08-21 2023-05-30 亚洲大学校产学协力团 由重链恒定区和轻链恒定区组成的γ恒定区（Cγ1）和ε恒定区（Cε2-4）融合的抗体片段及其用途
CN114426974A (zh) * 2020-10-29 2022-05-03 洛阳普泰生物技术有限公司 非洲猪瘟病毒CD2v蛋白及由其制备的试剂盒和抗体
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
CN117120479A (zh) * 2020-11-02 2023-11-24 阿特拉斯公司 Sap fc融合蛋白及其使用方法
WO2023025120A1 (en) * 2021-08-24 2023-03-02 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
CN116064562A (zh) * 2022-10-28 2023-05-05 江南大学 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途
CN116284455B (zh) * 2023-04-17 2024-10-11 北京康乐卫士生物技术股份有限公司 一种带状疱疹病毒疫苗的嵌合抗原及其应用
CN116284455A (zh) * 2023-04-17 2023-06-23 北京康乐卫士生物技术股份有限公司 一种带状疱疹病毒疫苗的嵌合抗原及其应用
WO2025162458A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 融合抗体及其制备和应用
CN118344462A (zh) * 2024-06-18 2024-07-16 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN119613573A (zh) * 2025-02-14 2025-03-14 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN119735654A (zh) * 2025-02-27 2025-04-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用
CN120623322A (zh) * 2025-08-14 2025-09-12 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用
CN120623322B (zh) * 2025-08-14 2025-12-05 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用
CN120923615A (zh) * 2025-08-15 2025-11-11 成都蓉生药业有限责任公司 一种人IgG1 Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG1 Fc变体的制备方法和应用
CN120923615B (zh) * 2025-08-15 2026-07-03 成都蓉生药业有限责任公司 一种人IgG1 Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG1 Fc变体的制备方法和应用

Also Published As

Publication number Publication date
MX2016001165A (es) 2016-06-29
AU2022201204B2 (en) 2025-01-02
AU2020200329A1 (en) 2020-02-06
EP3027647A2 (en) 2016-06-08
IL243690B (en) 2022-09-01
CA2919076C (en) 2024-01-30
JP2016526909A (ja) 2016-09-08
HK1224203A1 (zh) 2017-08-18
KR20230141929A (ko) 2023-10-10
EA201690299A1 (ru) 2016-11-30
WO2015017548A2 (en) 2015-02-05
KR20160034404A (ko) 2016-03-29
KR20250152665A (ko) 2025-10-23
WO2015017548A3 (en) 2015-11-05
US20160193295A1 (en) 2016-07-07
MX2022008013A (es) 2022-07-27
EA035319B1 (ru) 2020-05-27
US20190192628A1 (en) 2019-06-27
AU2022201204A1 (en) 2022-03-17
EP3027647A4 (en) 2017-01-04
CN121930334A (zh) 2026-04-28
CA2919076A1 (en) 2015-02-05
CL2016000232A1 (es) 2016-09-02
IL243690A0 (en) 2016-04-21
JP7344858B2 (ja) 2023-09-14
BR112016002219A2 (pt) 2017-09-12
SG11201600734YA (en) 2016-02-26
AU2014296215A1 (en) 2016-02-11
US20250325631A1 (en) 2025-10-23
JP2021019598A (ja) 2021-02-18

Similar Documents

Publication Publication Date Title
US20250325631A1 (en) Stabilization of fc-containing polypeptides
US11591397B2 (en) Bispecific antibody molecules binding to CD3 and EGFRvIII
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
US20230416411A1 (en) Antibodies binding to cd3 and folr1
CA3000869A1 (en) Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
CN106397598B (zh) 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
EP3452502B1 (en) The contorsbody - a single chain target binder
TW201100543A (en) Tri-or tetraspecific antibodies
CN114174344B (zh) 工程改造铰链区以驱动抗体二聚化
JP2016531581A (ja) 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
CN118369349A (zh) 与cd3和plap结合的抗体
WO2023118241A1 (en) Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof
US12297273B2 (en) Fc variant with enhanced affinity to Fc receptors and improved thermal stability
CN117651714A (zh) 多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
WO2025088546A1 (en) Fc domain variants with enhanced fc receptor binding

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination